Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 159 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Immune Pathways Help Identify Patients with Cancer and HIV Most Likely... March 9, 2026 New on NCI’s Websites for September 2020 September 2, 2020 Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... April 22, 2021 EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin June 12, 2025 Load more HOT NEWS Girl Whose Insides Were Sucked From Her Body While Sitting On... New analysis reveals Black women in England more likely to be... ESMO Recommendations on Cancer Care Reflected in Un ECOSOC Ministerial Declaration... In memory of Dame Deborah James
